US and Europe Gene Editing Market to Grow at a CAGR of 18.2% to reach US$ 15,052.92 million from 2023 to 2030

The US and Europe gene editing market size is expected to reach US$ 15,052.92 million in 2030 from US$ 3,955.09 million in 2022; the market is estimated to record a CAGR of 18.2% during 2023–2030.

Market Insights and Analyst View:

Continuous technological advancements in gene editing tools, the availability of government funding, an upsurge in the number of genomics projects, and a rise in the prevalence of cancer and other genetic disorders are a major factor driving the US and Europe gene editing market growth. Growing preference for personalized medicine, increase in private and public sector funding, and rapid advancements in sequencing and gene editing techniques are a few of the factors that are likely to propel the US and Europe gene editing market growth in the coming years. Developments in CRISPR-based novel diagnostic tools to mitigate the adversities associated with the COVID-19 pandemic have benefitted the market in recent years. Key players in emerging economies and expanding fields of applications in several drug discovery studies are a few factors that provide notable opportunities to the US and Europe gene editing market players. In November 2020, Eli Lilly partnered with Precision BioSciences to use the ARCUS platform for the R&D of potential in vivo therapies for genetic disorders in collaboration with Durham, NC, a developer of therapies based on gene editing as well as “off-the-shelf” CAR T immunotherapies.

Growth Drivers and Challenges:

Rise in Prevalence of Cancer and Genetic Disorders

According to the World Health Organization (WHO), cancer was the cause of approximately 10 million deaths in the world in 2020. Overall, the global burden of cancer incidence and death is quickly increasing. As per the Centers for Disease Control and Prevention (CDC), in 2020, 1.6 million new cancers cases were reported, and 602,347 people died of cancer in the US. Hepatocellular carcinoma (HCC) is known to be the second leading cause of cancer-related deaths worldwide. According to the CDC, ~21,000 men and ~8,000 women develop liver cancer annually in the US. In 2021, 134,802 people in England died from cancer. The number of deaths has increased by 6% since 2001. As per the Macmillan Cancer Support, in 2022, ~3 million people had cancer in the UK; the number is expected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040.

A chromosomal abnormality can be detected in nearly one out of every 150 live births. However, this is only a small fraction of chromosome mutations since most are lethal and result in prenatal death or stillbirth. 50% of all first-trimester miscarriages and 20% of all second-trimester miscarriages are estimated to involve a chromosomally abnormal fetus. Although Down syndrome is the most well-known and well-recognized autosomal trisomy, it is only diagnosed in ~1 out of every 800 live births.

Many cancer biology investigation groups are now using CRISPR as a standard approach. The CRISPR/Cas9 system has been observed to be effective in treating metastatic tumors. The CRISPR-LNP system contains a messenger RNA that translates the Cas9 CRISPR enzyme, which operates as molecular scissors to cut the DNA. CRISPR-based studies have opened new doors to treating hereditary or developmental neurological disorders (HNDs) such as fragile X syndrome and Down syndrome.

Thus, the increasing cases of cancer and genetic disorders propel the growth of the US and Europe gene editing market.

Report Segmentation and Scope:

The “US and Europe Gene Editing Market” is segmented on the basis of technology, product and service, application, end user, and geography. Based on technology, the market is segmented into CRISPR, TALEN, antisense, Zinc Finger Nucleases (ZFNs), and others. The US and Europe gene editing market, by product and service, is segmented into reagents and consumables, instruments, and others. In terms of application, the US and Europe gene editing market is segmented into cell line engineering, genetic engineering, diagnostic application, drug discovery, and others. The US and Europe gene editing market, based on country, is segmented into the US and Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe).

Segmental Analysis:

Based on technology, the US and Europe gene editing market is categorized into CRISPR, TALEN, antisense, Zinc Finger Nucleases (ZFNs), and others. In 2022, the CRISPR segment held the largest share of the market. Moreover, the same segment is also expected to register the fastest CAGR during the forecast period. The clustered regularly interspaced short palindromic repeats (CRISPR) are associated with Cas genes essential for adaptive immunity in selected bacteria and archaea. CRISPR enables organisms to respond to the changes and eliminate the invading genetic material. Three types of CRISPR mechanisms have been adopted for genome-editing protocols—wild-type Cas9, mutated Cas9, and nuclease-deficient Cas9.

CRISPR-Cas9 is faster, cheaper, and more accurate than other technologies of DNA editing and is used for a wide range of applications. It is considered the simplest, most versatile, and precise method of genetic manipulation. Sangamo Therapeutics, Editas Medicine, ThermoFisher Scientific, and Horizon Discovery Groups are among the companies that offer CRISPR tools and consumables associated with them.

US and Europe Gene Editing Market, by Technology – 2022 and 2030

Based on product and service, the US and Europe gene editing market is segmented into reagents and consumables, instruments, and others. In 2022, the reagents and consumables segment held the largest share of the market. The same segment is expected to record the highest CAGR during the forecast period. The market dominance of the reagents and consumables segment is primarily attributed to the sales volume achieved through their extensive use in the industry. Reagents such as azidothymidine, abscisic acid, brefeldin A, and nocodazole are widely used in laboratories and institutes with genetic engineering facilities. With the increasing number of laboratories, hospitals, and academic institutions, the use of reagents and consumables would rise as well, further consolidating the market growth.

Based on application, the US and Europe gene editing market is categorized into cell line engineering, genetic engineering, diagnostic application, drug discovery, and others. In 2022, the cell line engineering segment held the largest market share. The market for the same segment is expected to grow at the fastest CAGR during the forecast period. Cell line engineering is majorly performed in laboratories, to understand the basic biology behind diseases and therapeutics. Cell line engineering provides benefits such as optimizing cell lines for recombinant protein expression and characterizing the protein profile of genetically modified organisms. Cell line engineering enables the production of various industrial and commercial products that gain much more revenue as the products are produced per the requirement.

Based on end user, the US and Europe gene editing market is segmented into pharmaceutical & biotechnology companies, academic and research institutes, contract research organizations (CROs), and others. In 2022, the pharmaceutical & biotechnology companies segment held the largest share of the market. The academic and research institutes segment is expected to register the highest CAGR during the forecast period. Academic and research institutes have developed various technologies in the field of genomics. For instance, the National Institutes of Health (NIH) and the United States Department of Agriculture (USDA) have developed a new technique that will aid in a more specific reconstruction of genomes, specifically in determining the sections of the genome coming from each parent. Findings regarding the new technique were published in the journal Nature Biotechnology. The gene editing market for the CRO segment is growing owing to the benefits conferred by outsourcing processing to CROs, especially in terms of cost-saving and time taken by research activities.

Regional Analysis:

The gene editing market in the US was valued at US$ 2,169.04 million in 2022 and is projected to reach US$ 8,376.43 million by 2030; it is expected to grow at a CAGR of 18.4% during the forecast period. The growth of the US and Europe gene editing market is driven by the increasing prevalence of genetic disorders and the rising adoption of advanced gene therapies to treat chronic diseases. According to the US Genetic and Rare Disease Information Center, ~1 in 10 people (~30 million) in the US have a genetic or rare disease. For instance, the data published by the NIH's National Library of Medicine in July 2021, cystic fibrosis is among the most common genetic diseases observed in the US population. The incidence rate for the disease is 1 in 2,500–3,500 newborns. However, the incidence of cystic fibrosis is relatively lower among other ethnic groups in the country. The disease incidence among these groups is ~1 in 17,000 African Americans and 1 in 31,000 Asian Americans. The rising adoption of cancer gene therapy for treatment and the introduction of associated products by the gene editing market players, along with the support by regulatory agencies for the commercialization of such products, are also expected to fuel the market growth in the US in the future. In May 2021, the US Food and Drug Administration (FDA) approved Lumakras (Sotorasib) as a targeted therapy for non-small cell lung cancer patients with tumors that express the G12C mutation in the KRAS gene.

According to SeedScientific, there are ~6,600 registered biotechnology companies and over 2,000 pharmaceutical companies in the US. In March 2021, scientists from the University of California (UC) San Francisco, UC Berkeley, and UC Los Angeles received approval from the FDA to jointly initiate an early phase, first-in-human gene editing clinical trial of a correction therapy for patients with sickle cell anemia using their own hematopoietic stem cells. In October 2020, Merck signed a license agreement with Takara Bio USA, Inc. Through this agreement, Merck licensed its CRISPR technology to Takara to develop vectors and other innovative products to facilitate research using CRISPR and cell engineering services, specifically stem cells. In February 2022, Integrated DNA Technologies, Inc (IDT, US) launched Alt-R HDR Donor Blocks to advance homology-driven repair gene editing research. IDT's Alt-R HDR Donor Blocks are an improved technique that is meant to increase the use of homology-directed repair (HDR) in vital studies of large fragments of DNA.

The European genome editing market is divided into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The market growth in the region is attributed to the growing life science research and the increase in investments in research and development.

Industry Developments and Future Opportunities: 

Various initiatives taken by key players operating in the US and Europe gene editing market landscape are listed below:

1. In March 2021, IDT, a leading comprehensive genomics solutions provider, announced the acquisition of Swift Biosciences, a pioneer in developing next-generation sequencing (NGS) library preparation genomics kits for academic, translational, and clinical research.
2. In November 2022, ElevateBio, LLC unveiled its BaseCamp’s proprietary LentiPeak lentiviral vector platform. LentiPeak is a serum-free, suspension-based, scalable production platform that demonstrates high volumetric productivity of therapeutically relevant vector yields in adherence to regulatory guidelines. LentiPeak would enable an efficient transition for cell and gene therapies from the preclinical stage through clinical development and commercialization with accelerated timelines and reduced costs. The LentiPeak platform leverages ElevateBio BaseCamp’s end-to-end process, analytical development expertise, and scientific leadership in the gene editing market.
3. In October 2022, Merck, a leading science and technology company, announced signing agreements licensing its CRISPR technology to two companies—PanCELLa, a cell therapy firm based in Toronto, Canada, and Takara Bio USA, Inc., a biotechnology company based in Mountain View, California, US.

COVID-19 Impact:

As per the study titled "Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening" published in the Journal Viruses in June 2022, researchers have described the creation of a suitable human cell line for the high-throughput testing of antiviral medications that target SARS-Cov-2. Angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), two essential host proteins required for viral entry into the host body, were engineered to express high levels in the human lung carcinoma cell line A549. The resultant development of more cell lines to manage COVID-19 had a significant impact on the US and Europe gene editing market in the last few years.

Competitive Landscape and Key Companies:

A few of the prominent players operating in the US and Europe gene editing market include Thermo Fisher Scientific Inc.; Merck KGaA; Lonza; PerkinElmer.; Integrated DNA Technologies; GenScript; New England Biolabs; Eurofins Scientific; CRISPR Therapeutics; Editas Medicine; and ElevateBio. Thermo Fisher Scientific Inc. and Merck KGaA are the dominant players in the gene editing market. These companies focus on new product launches and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which allows them to serve a large set of customers, subsequently expanding their share in the US and Europe gene editing market.

US and Europe Gene Editing Report Scope